Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored vs Fixed Dose Albumin in Cirrhosis with Sepsis-Associated AKI
NCT06809088Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in acute kidney injury (AKI) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients having resolution of AKI without adverse events at 7 days. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
albumin (human)
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06809088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809088.